Canadian Blood Services

John Freedman

Alan H. Lazarus

Davor Brinc

Seng Song

Vinayakumar Siragam

Andrew R. Crow

Andrew R Crow

Alan H Lazarus

A method of cell-based therapy for treating an autoimmune disease is disclosed. The method is directed at stimulating leukocytes and/or dendritic cells to interrupt autoimmunity in a host. The method provides a Fc&#x3b3; receptor-specific complex or a complex which results in the co-crosslinking of Fc&#x3b3;-chains for treating the leukocytes and/or dendritic cells which are in turn used to elicit an autoimmune interruption response in a subject with an autoimmune disease. The Fc&#x3b3; receptor-specific complex and/or complex which results in the co-crosslinking of Fc&#x3b3;-chains is used to treat a biological sample comprising leukocytes and/or dendritic cells from a patient, and upon reintroducing said biological sample to the patient, the pre-treated dendritic cells illicit an autoimmune interruption response in vivo.

Method for treating autoimmune diseases and compositions therefor

The invention relates to a method for inhibiting an in vivo alloimmune response, and to the use of a soluble recombinant human CD40L protein containing the active binding site with CD40. In particular, a soluble 18 KDa recombinant CD40L is used to inhibit an in vivo alloimmune response.

Methods of inhibiting platelet anti-HLA alloimmune antibody responses with soluble 18 KDa CD40L

The present invention relates to a method for preventing HLA alloimmune response to platelet transfusion. The method comprises the step of presensitizing platelets with at least one monoclonal HLA antibody. The platelets if administered to a patient prevent an HLA alloimmune response from said patient.

Method for preventing and inhibiting human HLA alloimmune response to platelet transfusion

Growing community of inventors

Toronto, Canada

Andrew R Crow